Ajanta Pharma Ltd. Reports Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016
January 24, 2017 at 09:24 am
Share
Ajanta Pharma Ltd. reported unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2016. On standalone basis, for the quarter, the company reported total income from operations of INR 5,331.1 million against INR 4,766.4 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 1,626.8 million against INR 1,518.2 million a year ago. Profit from ordinary activities before finance costs and tax was INR 1,818.7 million against INR 1,541.4 million for the same period in the last year. Net profit was INR 1,426.0 million or INR 16.20 per diluted share against INR 1,139.4 million or INR 12.95 per diluted share for the same period in the last year. EBITDA growth was 9% at INR 1,780 million against INR 1,640 million a year ago.
For the nine months, on consolidated basis, the company reported total income from operations of INR 15,248.3 million against INR 13,137.9 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 4,853.2 million against INR 4,073.2 million a year ago. Profit from ordinary activities before finance costs and tax was INR 5,067.9 million against INR 4,234.2 million for the same period in the last year. Net profit was INR 3,928.1 million or INR 44.63 per diluted share against INR 3,033.9 million or INR 34.48 per basic and diluted share for the same period in the last year. EBITDA growth was 20% at INR 5,280 million against INR 4,400 million a year ago.
For the quarter, on standalone basis, the company reported total income from operations of INR 5,086.0 million against INR 4,238.9 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 1,607.7 million against INR 1,382.1 million a year ago. Profit from ordinary activities before finance costs and tax was INR 2,118.5 million against INR 1,431.3 million for the same period in the last year. Net profit was INR 1,709.8 million or INR 19.42 per basic and diluted share against INR 1,038.9 million or INR 11.80 per basic and diluted share for the same period in the last year.
For nine months, on standalone basis, the company reported net sales of INR 14,042.1 million against INR 11,621.0 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 4,535.1 million against INR 3,556.1 million a year ago. Profit from ordinary activities before finance costs and tax was INR 5,131.0 million against INR 3,992.3 million for the same period in the last year. Net profit was INR 3,918.4 million or INR 44.52 per basic and diluted share against INR 2,807.0 million or INR 31.89 per basic and diluted share for the same period in the last year.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
AJANTA PHARMA LIMITED 
